Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Treatment Strategies for Psychological Disorders01:24

Treatment Strategies for Psychological Disorders

Treatment approaches for psychological disorders fall into three main categories: psychological, biological, and sociocultural. Each approach targets different aspects of mental health, requiring varying levels of education and training.
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
Depressive Disorders: MDD and Dysthymia01:27

Depressive Disorders: MDD and Dysthymia

Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
Depression: Overview01:18

Depression: Overview

Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
Cognitive Therapy01:25

Cognitive Therapy

Cognitive therapy, pioneered by Aaron T. Beck in the 1960s, is a structured approach to addressing psychological distress by focusing on the influence of thoughts on emotions and behaviors. All cognitive therapies involve the basic assumption that human beings have control over their feelings, and that how individuals feel about something depends on how they think about it. Unlike psychoanalytic methods that delve into unconscious processes or humanistic approaches emphasizing...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Psychometric Properties of the Concise Associated Symptom Tracking Scale and Validation of Clinical Utility in the EMBARC Study.

Psychiatric research and clinical practiceยท2022
Same author

BLENDS: Augmentation of Functional Magnetic Resonance Images for Machine Learning Using Anatomically Constrained Warping.

Brain connectivityยท2022
Same author

Circulating microRNA associated with future relapse status in major depressive disorder.

Frontiers in psychiatryยท2022
Same author

Dynamic Resting-State Network Biomarkers of Antidepressant Treatment Response.

Biological psychiatryยท2022
Same author

Alterations in resting-state functional activity and connectivity for major depressive disorder appetite and weight disturbance phenotypes.

Psychological medicineยท2022
Same author

Youth Aware of Mental Health (YAM) Program With Texas Adolescents: Depression, Anxiety, and Substance Use Outcomes.

The Journal of clinical psychiatryยท2022

Related Experiment Video

Updated: Jun 2, 2026

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

Challenges and algorithm-guided treatment in major depressive disorder.

Richard C Shelton1, Madhukar H Trivedi

  • 1Department of Psychiatry, Vanderbilt School of Medicine, Nashville, Tennessee, USA.

The Journal of Clinical Psychiatry
|April 30, 2011
PubMed
Summary

Major depressive disorder (MDD) is challenging to treat due to its chronic nature and limited medication effectiveness. Optimizing patient care with measurement-based approaches and treatment algorithms is crucial for managing depression symptoms and achieving remission.

More Related Videos

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
07:12

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

Related Experiment Videos

Last Updated: Jun 2, 2026

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
07:12

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

Area of Science:

  • Psychiatry
  • Clinical Psychology
  • Pharmacology

Background:

  • Major depressive disorder (MDD) presents significant treatment challenges owing to its chronic, recurrent nature and the often suboptimal efficacy of current pharmacologic interventions.
  • The complexity of MDD necessitates a shift from solely relying on medication to a more comprehensive patient-centered approach.

Discussion:

  • Optimizing patient care is paramount in managing MDD, especially when definitive treatment breakthroughs are pending.
  • Implementing measurement-based care (MBC) provides a structured framework for monitoring patient progress and adjusting treatment strategies dynamically.
  • Treatment algorithms offer a systematic pathway for clinicians to navigate therapeutic decisions, enhancing consistency and potentially improving outcomes.

Key Insights:

  • Measurement-based care (MBC) is a vital strategy for improving patient outcomes in major depressive disorder.
  • Treatment algorithms can streamline clinical decision-making, leading to better symptom reduction and remission rates.
  • A focus on patient care, incorporating MBC and algorithms, is essential for managing the complexities of MDD.

Outlook:

  • Further research into novel pharmacologic and non-pharmacologic treatments for MDD is ongoing.
  • Continued integration of MBC and treatment algorithms is expected to enhance the management of chronic and recurrent depression.
  • Improving patient adherence and therapeutic alliance remains a critical factor in achieving sustained remission for individuals with MDD.